| Dr Regan Marquis Prudhomme, OD | |
|
194 Buckland Hills Dr, Suite 1106, Manchester, CT 06042 | |
| (860) 644-3364 | |
| (860) 667-4377 |
| Full Name | Dr Regan Marquis Prudhomme |
|---|---|
| Gender | Female |
| Speciality | Optometrist |
| Location | 194 Buckland Hills Dr, Manchester, Connecticut |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548450588 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 002721 (Connecticut) | Primary |
| Provider Name | Prudhomme Vision Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1649504432 PECOS PAC ID: 6709182041 Enrollment ID: O20160311001107 |
News Archive
Eisai Corporation of North America has announced data from a Phase II trial evaluating a five-day dosing regimen of Dacogen(R) (decitabine for injection) in acute myeloid leukemia (AML), the most common form of leukemia.
Anika Therapeutics, Inc. today announced it has received marketing approval for MONOVISC from the U.S. Food and Drug Administration. MONOVISC is a single injection supplement to synovial fluid of the osteoarthritic joint, used to treat pain and improve joint mobility in patients suffering from osteoarthritis (OA) of the knee.
Hospital MRIs may be better at predicting long-term outcomes for people with mild traumatic brain injuries than CT scans, the standard technique for evaluating such injuries in the emergency room, according to a clinical trial led by researchers at the University of California, San Francisco (UCSF) and the San Francisco General Hospital and Trauma Center (SFGH).
Vical Incorporated today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $2.25 per share. The gross proceeds to us from this offering are expected to be approximately $33.8 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering is expected to close on or about September 29, 2010, subject to customary closing conditions.
A new nationally representative study shows a downward trend in the rate of "cognitive impairment" - the umbrella term for everything from significant memory loss to dementia and Alzheimer's disease - among people aged 70 and older.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Regan Marquis Prudhomme, OD 194 Buckland Hills Dr, Suite 1106, Manchester, CT 06042 Ph: (860) 644-3364 | Dr Regan Marquis Prudhomme, OD 194 Buckland Hills Dr, Suite 1106, Manchester, CT 06042 Ph: (860) 644-3364 |
News Archive
Eisai Corporation of North America has announced data from a Phase II trial evaluating a five-day dosing regimen of Dacogen(R) (decitabine for injection) in acute myeloid leukemia (AML), the most common form of leukemia.
Anika Therapeutics, Inc. today announced it has received marketing approval for MONOVISC from the U.S. Food and Drug Administration. MONOVISC is a single injection supplement to synovial fluid of the osteoarthritic joint, used to treat pain and improve joint mobility in patients suffering from osteoarthritis (OA) of the knee.
Hospital MRIs may be better at predicting long-term outcomes for people with mild traumatic brain injuries than CT scans, the standard technique for evaluating such injuries in the emergency room, according to a clinical trial led by researchers at the University of California, San Francisco (UCSF) and the San Francisco General Hospital and Trauma Center (SFGH).
Vical Incorporated today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $2.25 per share. The gross proceeds to us from this offering are expected to be approximately $33.8 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering is expected to close on or about September 29, 2010, subject to customary closing conditions.
A new nationally representative study shows a downward trend in the rate of "cognitive impairment" - the umbrella term for everything from significant memory loss to dementia and Alzheimer's disease - among people aged 70 and older.
› Verified 7 days ago
Dr. Jennifer L Stroh, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 178 Hartford Rd, Manchester, CT 06040 Phone: 860-649-9973 | |
George Raymond Stimac, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 125 Buckland Hills Dr, @ Target Optical, Manchester, CT 06042 Phone: 860-327-0085 Fax: 860-327-0087 | |
Dr. Christina Vu, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 190 Buckland Hills Dr, Manchester, CT 06042 Phone: 860-644-7541 Fax: 860-648-2102 | |
National Vision Inc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1470d Pleasant Valley Rd, Manchester, CT 06042 Phone: 860-812-6267 | |
Robert T Yarosh, OD Optometrist Medicare: Medicare Enrolled Practice Location: 164 E Center St, Manchester, CT 06040 Phone: 860-649-2020 Fax: 860-643-1252 | |
Dr. Danielle Gurciullo, OD Optometrist Medicare: Medicare Enrolled Practice Location: 362 Middle Tpke W, Manchester, CT 06040 Phone: 860-649-3311 | |
Lance I Alpert, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 362 West Middle Tpke, Manchester, CT 06040 Phone: 860-649-3311 Fax: 860-533-1960 |